Applied Genetic Technologies Corporation (NASDAQ: AGTC) is 3.10% higher on its value in year-to-date trading and has touched a low of $2.29 and a high of $10.42 in the current 52-week trading range. The AGTC stock was last observed hovering at around $4.08 in the last trading session, with the day’s gains setting it 0.58% off its average median price target of $14.00 for the next 12 months. It is also 81.36% off the consensus price target high of $25.00 offered by analysts, but current levels are 37.87% higher than the price target low of $7.50 for the same period.
Currently trading at $4.66, the stock is 18.03% and 26.65% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 507619.0 and changing 14.22% at the moment leaves the stock 16.89% off its SMA200. AGTC registered 14.22% gain for a year compared to 6-month gain of 61.25%. The firm has a 50-day simple moving average (SMA 50) of $3.6784 and a 200-day simple moving average (SMA200) of $4.2272.
The stock witnessed a 28.55% loss in the last 1 month and extending the period to 3 months gives it a -6.80%, and is 18.27% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.67% over the week and 7.87% over the month.
Applied Genetic Technologies Corporation (AGTC) has around 85 employees, a market worth around $119.48M and $24.20M in sales. Profit margin for the company is -79.50%. Distance from 52-week low is 103.49% and -55.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-5.60%).
Applied Genetic Technologies Corporation (AGTC) Analyst Forecasts
Applied Genetic Technologies Corporation is expected to release its quarterly report on 05/12/2020 and quarterly earnings per share for the current quarter are estimated at -$0.55 with sales reaching $30k over the same period.The EPS is expected to grow by 90.90% this year, but quarterly earnings will post -98.00% year-over-year.
Applied Genetic Technologies Corporation (AGTC) Top Institutional Holders
66 institutions hold shares in Applied Genetic Technologies Corporation (AGTC), with 170.33k shares held by insiders accounting for 0.93% while institutional investors hold 48.64% of the company’s shares. The shares outstanding are 25.64M, and float is at 24.49M with Short Float at 3.58%. Institutions hold 48.19% of the Float.
The top institutional shareholder in the company is Interwest Venture Management Co. with over 1.46 million shares valued at $4.78 million. The investor’s holdings represent 7.99% of the AGTC Shares outstanding. As of Dec 30, 2019, the second largest holder is Renaissance Technologies, LLC with 1.21 million shares valued at $5.49 million to account for 6.67% of the shares outstanding. The other top investors are Dimensional Fund Advisors LP which holds 979723.0 shares representing 5.38% and valued at over $4.43 million, while Acadian Asset Management holds 3.87% of the shares totaling 704855.0 with a market value of $3.19 million.
Applied Genetic Technologies Corporation (AGTC) Insider Activity
A total of 2 insider transactions have happened at Applied Genetic Technologies Corporation (AGTC) in the last six months, with sales accounting for 1 and purchases happening 1 times. The most recent transaction is an insider sale by Krol Patrick Johan Hendrik, the company’s 10% Owner. SEC filings show that Krol Patrick Johan Hendrik sold 81,162 shares of the company’s common stock on Dec 26 at a price of $5.24 per share for a total of $425289.0. Following the sale, the insider now owns 1.78 million shares.
Applied Genetic Technologies Corporation disclosed in a document filed with the SEC on Nov 19 that Krol Patrick Johan Hendrik (10% Owner) bought a total of 2,544 shares of the company’s common stock. The trade occurred on Nov 19 and was made at $2.79 per share for $7098.0. Following the transaction, the insider now directly holds 1.86 million shares of the AGTC stock.
Applied Genetic Technologies Corporation (AGTC): Who are the competitors?
The company’s main competitors (and peers) include Eiger BioPharmaceuticals Inc. (EIGR) that is trading 18.55% up over the past 12 months. Dicerna Pharmaceuticals Inc. (DRNA) is 113.78% up on the 1-year trading charts. Short interest in the company’s stock has fallen -8.82% from the last report on Mar 12, 2020 to stand at a total of 955110.0 short shares sold with a short interest ratio of 3.99.